Physicochemical stability evaluation of liquid extemporaneous preparation based on tretinoin for administration via enteral tuve
DOI:
https://doi.org/10.30968/rbfhss.2024.151.0927Abstract
Objective: The purpose of the study was to evaluate the content and physicochemical stability of a liquid oral formulation obtained from ATRA gelatin capsules in an oil/water vehicle, given the demand for this formulation for intubated patients undergoing treatment for acute promyelocytic leukemia. Methods: Analyzes were performed using High Performance Liquid Chromatography (HPLC) coupled to a UV detector, using a C-18 column. The run was performed with a mobile phase composed of ultrapure water with 0.5% glacial acetic acid (v/v) as solvent A and acetonitrile as solvent B, in an isocratic run (25:75) (A/B) with a flow of 1 mL/min, temperature at 30°C and detection at 355 nm. The sample injection was 10 μL and the run time was 12 min. The oral formulations were prepared from ATRA (Vesanoid, FQM) in mineral oil/ultrapure water (3:7) (v/v) by dissolution process and heating at 40°C, in oral dosers protected from light and kept under refrigeration (2 – 8°C). Analyzes were performed on days 1, 2, 3, 7, 9 and 14. Results: The extemporaneous preparation showed acceptable visual physical stability, with a change in appearance due to the hardening of aqueous phase, corrected by heating the formulation in water bath at 40°C. The ATRA content was considered adequate until D3 according to the Brazilian Pharmacopeia (FB) 6th edition, presenting 103.3%, 94.8% and 95.6%, on days 1, 2 and 3, respectively. The concentration of isotretinoin, a degradation product, varied from 0.16% to 1.44%, between days 1 and 14, respectively. Conclusion: The results suggested that the liquid oral preparation presented satisfactory content and physicochemical stability for up 48 hours after preparation, when stored protected from light and under refrigeration, as recommended by RDC 67/2007.
Downloads
References
WHO. Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. International Agency for Research on Cancer (IARC), Lyon 2017.
Warrell Jr, RP, de The, H, Wang, ZY, et al. Acute promyelocytic leukemia. New England Journal of Medicine, 1993;329(3):177-189. doi: 10.1056/NEJM199307153290307
de The, H. Differentiation therapy revisited. Nature Reviews Cancer, 2018; 18(2):117-127. doi: 10.1038/nrc.2017.103
Rowe, JM, Tallman, MS. How I treat acute myeloid leukemia. Blood, The Journal of the American Society of Hematology, 2010; 116(17):3147-3156. doi: 10.1182/blood-2010-05-260117
Brunton, LL, Chabner, BA, Knollmann, BC. As bases farmacológicas da terapêutica de Goodman & Gilman, 12ª edição. Porto Alegre: AMGH Editora; 2012.
Pinheiro, RF, Pelloso, LAF, Mihoko, Y, et al. Síndrome Atra: experiencia de 10 anos. Revista Brasileira de Cancerologia, 2003; 49(1):27-31. doi: 10.32635/2176-9745.RBC.2003v49n1.2120
Ministério da Saúde. Agência Nacional de Vigilância Sanitária (ANVISA). Consulta de Medicamentos. Tretinoína. Available in: https://consultas.anvisa.gov.br/#/medicamentos/25351244135201789/?substancia=9162. Accessed on: 23rd Oct 2023.
NIOSH List of antineoplastic and other hazardous drugs in healthcare settings. Atlanta, USA: National Institute of Occupational Safety and Health (NIOSH), Department of Health and Human Services, Center for Disease Control and Prevention; 2020. Available in: https://www.cdc.gov/niosh/docket/review/docket233c/pdfs/DRAFT-NIOSH-Hazardous-Drugs-List-2020.pdf. Accessed on: 12nd Dec 2022.
Przybylski, DJ, Jared, JR, Fallon, MJ. Extemporaneous compounding and administration of tretinoin slurry for acute promyelocytic leukemia. Journal of Oncology Pharmacy Practice, 2021; 27(7):1779-1783. doi: 10.1177/1078155221990091
Okumura, LM, Baruel-Okumura, PC, Veroneze, C. Administration of all-trans retinoic acid through enteral tubes in acute promyelocytic leukemia: the handling of cytotoxic agents and clinical benefits. Revista Brasileira de Hematología e Hemoterapia, 2017; 39(1):86-88. doi: 10.1016/j.bjhh.2016.11.001
Lam, MSH. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2011; 31(2):164-192. doi: 10.1592/phco.31.2.164
Lara, VCD. Desenvolvimento de nanocápsulas contendo ácido retinóico pata tratamento tópico da acne [Dissertação de mestrado]. UFMG, Belo Horizonte, 2008.
UNITED STATES PHARMACOPEIA. Pharmacopeial Forum Volume n°41 – Tretinoin, 2019. Available in: https://online.uspnf.com/uspnf/document/GUID-23BED26C-AC53-40B7-AB07-12B20ECCF72A-3-en-US?highlight=tretinoin. Acessed on: 21st Dec 2021.
Roy, C, Chakrabarty, J. Stability indicating RP-HPLC method development and validation for determination of potential degradation impurities of tretinoin in tretinoin topical pharmaceutical formulation. Der Pharmacia Sinica, 2013; 4(4):6-14. doi: 10.3797/scipharm.1303-22
BRASIL, Agência Nacional de Vigilância Sanitária. Comissão da Farmacopeia Brasileira. Formulário Nacional da Farmacopeia Brasileira. 6ª edição, Volume 2. Brasília, 2019. Available in: https://www.gov.br/anvisa/pt-br/assuntos/farmacopeia/farmacopeia-brasileira/insumos-farmaceuticos-e-especialidades-ate-2a-errata-p-pdf-com-capa.pdf. Accessed on: 23th Oct 2023.
BRASIL, Agência Nacional de Vigilância Sanitária. Resolução RDC n°67, de 8 de outubro de 2007. Dispõe sobre Boas Práticas de Manipulação de Preparações Magistrais e Oficinais para Uso Humano em farmácias. Brasília, 2007. Available in: https://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2007/rdc0067_08_10_2007.html. Accessed on: 20th Nov 2023.
BRASIL, Agência Nacional de Vigilância Sanitária. Resolução n° 01, de 29 de julho de 2005. Guia para realização de estudos de estabilidade. Brasília, 2005. Available in: https://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2005/res0001_29_07_2005. html. Accessed on: 30th Jan 2023.
Diniz, D, Lima, EM, Antoniosi Filho, NR. Isotretinoína: perfis farmacológico, farmacocinético e analítico. Revista Brasileira de Ciências Farmacêuticas, 2002; 38(1):415-430. doi:10.1590/S1516-93322002000400004
Herceglija, EI. Stability testing of all-trans-retinol in an experimental cosmetic formulation and in methanol and methanol containing butylhydroxytoluene (BHT) using reversed-phase HPLC, 2021. Available in: https://www.diva-portal.org/smash/get/diva2:1598594/FULLTEXT01.pdf. Accessed on: 22nd Dec 2022.
British Pharmacopoeia. Medicines & Healthcare products Regulatory Agency. Monographs: Tretinoin. Available in: ile:///D:/BP 2023/bp-2023/Monographs pdfs/tretinoin [webofpharma.com].html. Accessed: 13rd Oct 2023.
UNITED STATES PHARMACOPEIA. General Chapters <795> Pharmaceutical Compounding – Nonsterile Preparations, 2020. Available in: https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/revisions/gc-795-rb-notice-20200424.pdf. Accessed on: 13rd Feb 2023.
Sahnoune, M., Tokhadze, N, El Kettani, SEC, et al. Drug interactions with plasticized PVCs. ACS Applied Polymer Materials, 2022; 4(6):4538-4550. doi: 10.1021/acsapm.2c00532
Allwood, MC. Drug interactions with plastics and their biological consequences. Biodeterioration 7, 1988; p. 157-162. doi: 10.1007/978-94-009-1363-9-21
National Center for Biotechnology Information. PubChem Compound Summary for CID 444795, Tretinoin. Available in: https://pubchem.ncbi.nlm.nih.gov/compound/Tretinoin. Accessed on: 12th Dec 2022.
Takitani, K, Nakao, Y, Kosaka, Y, et al. Low plasma level of alltrans retinoic acid after feeding tube administration for acute promyelocytic leukemia. American Journal of Hematology, 2004; 76(1):94–95. doi: 10.1002/ajh.2004
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Serlf-archiving policy
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.
